Loading patent…
AssigneeDuke University
InventorsThomas Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
Estimating the term…
The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
1-27. (canceled)
A method of treating a B cell malignancy in a human patient comprising;
30-34. (canceled)
38-40. (canceled)
43-50. (canceled)
52-57. (canceled)
59-63. (canceled)
Dependencies are inferred from the claim text.